Impact of Atrial Fibrillation Prediction Model on Prescribing Oral Anti-Coagulation in Patients With Cryptogenic Stroke

ClinicalTrials.gov ID: NCT07934511

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07934511. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Prediction of Atrial Fibrillation in Patients With Embolic Stroke of Unknown Source

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Stroke is a major cause of disability and the second leading cause of death in adults. Some strokes are linked to atrial fibrillation (AF), a type of irregular heartbeat. When AF is found, doctors usually prescribe blood-thinning medicines to help prevent another stroke. If AF is not found, patients are usually treated with antiplatelet medicines, such as aspirin. However, AF can be difficult to detect. Because of this, doctors may not know which treatment is best. Our research team has developed computer programs that analyze a normal electrocardiogram (EKG) and predict whether a person may develop AF in the future. These programs have been shown to be highly accurate. The goal of this study is to see how sharing these prediction results affects treatment decisions made by patients who have had an embolic stroke of undetermined source (ESUS) and their neurologist. An ESUS is a type of stroke where the exact cause cannot be identified. Participants in the study will have their normal EKG analyzed using the prediction program. Researchers will then evaluate whether providing these results to the neurologist influences decisions about the patient's care.

Study identification

NCT ID: NCT07934511
Recruitment status: Not yet recruiting
Study type: Interventional
Phase: Not applicable
Lead sponsor: Samir Saba; Other
Enrollment: 100 participants

Conditions and interventions

Conditions

Stroke

Interventions

UPMC AF Prediction Model Device

Device

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 2026 (Estimated)
Primary completion: Sep 2028 (Estimated)
Completion: Oct 2028 (Estimated)
Last update posted: Nov 13, 2026

2026 – 2028

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
UPMC	Pittsburgh	Pennsylvania	15213	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07934511, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 13, 2026 · Synced Nov 15, 2026